Unity Biotechnology

General Information


Our mission is to extend human healthspan. We define healthspan, or healthy longevity, as the period of one’s life unburdened by the diseases of aging. Enabled by foundational scientific insights, we have devoted over six years to identifying multiple mechanisms that we believe to be root causes of age-associated disease. We are utilizing these insights to develop a broad portfolio of drug candidates to treat these diseases of aging, and we plan to initiate our first clinical study of our lead drug candidate in the first half of 2018.


Employees: 67
Founded: 2009
Contact Information
Address 3280 Bayshore Blvd., Suite 100, Brisbane, CA 94005, US
Phone Number (650) 416-1192
Web Address http://www.unitybiotechnology.com
View Prospectus: Unity Biotechnology
Financial Information
Market Cap $712.3mil
Revenues $1.4 mil (last 12 months)
Net Income $-44.7 mil (last 12 months)
IPO Profile
Symbol UBX
Exchange NASDAQ
Shares (millions): 5.0
Price range $17.00 - $17.00
Est. $ Volume $85.0 mil
Manager / Joint Managers Goldman Sachs/ Morgan Stanley/ Citigroup
CO-Managers Mizuho Securities
Expected To Trade: 5/3/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change